Alzheimer's Disease: The Link Between Amyloid-β and Neurovascular Dysfunction

Ernesto Solis1, Kevin N Hascup1,2,3, Erin R Hascup1,2

  • 1Department of Neurology, Neuroscience Institute, Center for Alzheimer's Disease and Related Disorders, Southern Illinois University School of Medicine, Springfield, IL, USA.

Insights

Alzheimer's disease (AD) involves vascular issues like reduced cerebral blood flow (CBF) and blood-brain barrier damage, which precede amyloid-β plaque buildup. These vascular defects significantly contribute to AD progression and neurodegeneration.

Area of Science:

  • Neuroscience
  • Vascular Biology
  • Alzheimer's Disease Research

Background:

  • The amyloid cascade hypothesis is central to Alzheimer's disease (AD) pathology.
  • Emerging evidence highlights the significant role of vascular dysfunction in AD progression.
  • Vascular deficits, including reduced cerebral blood flow (CBF), precede hallmark AD pathologies like amyloid-β (Aβ) plaque accumulation.

Purpose of the Study:

  • To review Alzheimer's disease vascular disturbances linked to amyloid-β.
  • To emphasize the impact of Aβ on cerebral blood flow and neurovascular coupling.
  • To discuss findings on the interplay between vascular defects and Aβ accumulation.

Main Methods:

  • Review of existing literature on Alzheimer's disease and vascular pathology.
  • Focus on in vivo studies utilizing rodent AD models.
  • Analysis of Aβ effects on cerebral blood flow and neurovascular coupling.

Main Results:

  • Vascular dysfunction, including chronic cerebral hypoperfusion and hypertension, is evident in AD.
  • Amyloid-β impacts cerebral blood flow and neurovascular coupling.
  • Deterioration of the blood-brain barrier is a key feature of AD vascular pathology.

Conclusions:

  • Vascular disturbances are integral to Alzheimer's disease pathogenesis, not merely a consequence.
  • Understanding the relationship between vascular health and Aβ is crucial for AD treatment strategies.
  • Rodent AD models provide valuable insights into in vivo vascular changes associated with Aβ.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.4K
Amyloid Fibrils03:03

Amyloid Fibrils

6.2K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.9K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
663
The Blood-brain Barrier00:49

The Blood-brain Barrier

Overview
51.6K